Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial von Imel, Erik A, Glorieux, Francis H, Whyte, Michael P, Munns, Craig F, Ward, Leanne M, Nilsson, Ola, Simmons, Jill H, Padidela, Raja, Namba, Noriyuki, Cheong, Hae Il, Pitukcheewanont, Pisit, Sochett, Etienne, Högler, Wolfgang, Muroya, Koji, Tanaka, Hiroyuki, Gottesman, Gary S, Biggin, Andrew, Perwad, Farzana, Mao, Meng, Chen, Chao-Yin, Skrinar, Alison, San Martin, Javier, Portale, Anthony A

Volltext

Dietary and Serum Phosphorus Regulate Fibroblast Growth Factor 23 Expression and 1,25-Dihydroxyvitamin D Metabolism in Mice von Perwad, Farzana, Azam, Nasreen, Zhang, Martin Y. H, Yamashita, Takeyoshi, Tenenhouse, Harriet S, Portale, Anthony A

Volltext

Patient-reported outcomes from a randomized open-label phase 3 trial comparing burosumab versus conventional therapy in children with X-linked hypophosphatemia: results from the 24... von Padidela, Raja, Whyte, Michael P., Glorieux, Francis H., Munns, Craig F., Ward, Leanne M., Nilsson, Ola, Portale, Anthony A., Simmons, Jill H., Namba, Noriyuki, Cheong, Hae Il, Pitukcheewanont, Pisit, Sochett, Etienne, Högler, Wolfgang, Muroya, Koji, Gottesman, Gary S., Biggin, Andrew, Perwad, Farzana, Williams, Angela, Nixon, Annabel, Sun, Wei, Chen, Angel, Skrinar, Alison, Imel, Erik A.

Volltext

Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period von Ward, Leanne M, Högler, Wolfgang, Glorieux, Francis H, Portale, Anthony A, Whyte, Michael P, Munns, Craig F, Nilsson, Ola, Simmons, Jill H, Padidela, Raja, Namba, Noriyuki, Cheong, Hae Il, Sochett, Etienne, Muroya, Koji, Tanaka, Hiroyuki, Pitukcheewanont, Pisit, Gottesman, Gary S, Biggin, Andrew, Perwad, Farzana, Chen, Angel, Lawrence Merritt Ii, John, Imel, Erik A

Volltext

Fibroblast Growth Factor 23 Regulates Renal 1,25-Dihydroxy vitamin D and Phosphate Metabolism via the MAP Kinase Signaling Pathway in Hyp Mice von Ranch, D, Zhang, MY, Portale, A A, Perwad, F

Volltext

In Pediatric X-linked Hypophosphatemia (XLH), Burosumab Improved Clinical Outcomes Versus Higher and Lower Doses of Oral Phosphate and/or Active Vitamin D von Imel, EA, Glorieux, FH, Whyte, MP, Portale, AA, Munns, CF, Nilsson, O, Simmons, JH, Padidela, R, Namba, N, Cheong, HI, Pitukcheewanont, P, Sochett, E, Hogler, W, Muroya, K, Tanaka, H, Gottesman, GS, Biggin, A, Perwad, F, Chen, A, Roberts, MS, Ward, L

Volltext

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension von Briot, K, Portale, A.A, Brandi, M.L, Carpenter, T.O, Cheong, H.I, Cohen-Solal, M, Crowley, R.K, Eastell, R, Imanishi, Y, Ing, S, Insogna, K, Ito, N, Jan de Beur, S, Javaid, M.K, Kamenicky, P, Keen, R, Kubota, T, Lachmann, R.H, Perwad, F, Pitukcheewanont, P, Ralston, S.H, Takeuchi, Y, Tanaka, H, Weber, T.J, Yoo, H.-W, Nixon, A, Nixon, M, Sun, W, Williams, A, Imel, E.A

Volltext bestellen

Burosumab versus continuation of conventional therapy in children with X-linked hypophosphatemia: a randomised, active-controlled, open-label, phase 3 trial von Imel, Erik A., Glorieux, Francis H., Whyte, Michael P., Munns, Craig F., Ward, Leanne, Nilsson, Ola, Simmons, Jill H., Padidela, Raja, Namba, Noriyuki, Cheong, Hae Il, Pitukcheewanont, Pisit, Sochett, Etienne, Högler, Wolfgang, Muroya, Koji, Tanaka, Hiroyuki, Gottesman, Gary S., Biggin, Andrew, Perwad, Farzana, Mao, Meng, Chen, Chao-Yin, Skrinar, Alison, Martin, Javier San, Portale, Anthony A.

Volltext